TheraRadar
Clinical-Stage Companies / TJ Biopharma

TJ Biopharma

Pre-Approval PRO BETA
17
Total Trials
5
Phase 3
10
Phase 2
4
Recruiting
191
Score

Pipeline by Phase

Phase 3
5
Phase 2
10
Phase 1
7

Therapeutic Focus

Advanced Solid Tumor Non Small Cell Lung Cancer Myelodysplastic Syndromes(MDS) Multiple Myeloma in Relapse Refractory Multiple Myeloma

Clinical Trials (17)

NCT07208058 Phase 3 RECRUITING

A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])

Started: 11/21/2025

NCT05709093 Phase 3 TERMINATED

A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)

Started: 3/30/2023

NCT03952091 Phase 3 COMPLETED

TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Started: 3/27/2019

NCT04633057 Phase 3 COMPLETED

A Study to Evaluating the Efficacy and Safety of Recombinant Long-acting Human Growth Hormone (TJ101) in Children With Growth Hormone Deficiency

Started: 1/25/2021

NCT07453004 Phase 2 RECRUITING

A Study to Evaluate the Efficacy,Safety,Tolerability,Pharmacokinetics,and Immunogenicty of Plonmarlimab in Subjects With Acute Gouty Arthritis

Started: 3/26/2026

NCT07005336 Phase 2 ACTIVE NOT RECRUITING

A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer

Started: 1/9/2025

NCT06984588 Phase 2 ACTIVE NOT RECRUITING

A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer

Started: 3/28/2024

NCT07034209 Phase 2 COMPLETED

A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS))

Started: 4/7/2023

NCT03860038 Phase 2 COMPLETED

TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Started: 1/28/2019

NCT05338580 Phase 2 WITHDRAWN

Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors

Started: 12/31/2023

NCT04322006 Phase 1 COMPLETED

A Phase I/II Study of TJ004309 for Advanced Solid Tumor

Started: 5/9/2020

NCT07300436 Phase 1 COMPLETED

A Study of TJ101 Injection Before and After CMC Change Following Subcutaneous Injection in Healthy Adult Male Subjects in China

Started: 1/4/2026

NCT06285201 Phase 1 COMPLETED

Study of Felzartamab in Healthy Adult Subjects

Started: 3/27/2024

NCT05140824 Phase 1 TERMINATED

A Study to Evaluate the Safety, Tolerability, and PK Profile of Single and Multiple Doses TJ202 in Patient With Systemic Lupus Erythematosus

Started: 12/30/2021

NCT05148533 Phase 1 TERMINATED

A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor

Started: 12/30/2021

NCT04001075 Phase 1 COMPLETED

Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TJ107 in Chinese Patients With Advanced Solid Tumors

Started: 2/25/2019

NCT04202003 Phase 1 COMPLETED

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Started: 3/25/2020

Drug Candidates

TJ004309 Plonmarlimab Compound betamethasone Uliledlimab TJ101 injection Test Product TJ101 injection Reference Product T R Lemzoparlimab+Azacitidine (AZA) TJ202 and Dexamethasone
Activity Status: Active
Last Trial Started: 3/26/2026
Last Trial Ended: 3/16/2026
Trials (12 months): 3
Completed Trials: 9
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.